Research promotion and good partnerships have brought rare gynaecological malignancies into the light
According to Prof. Isabelle Ray-Coquard, 2023 ESMO Awardee, the many efforts made in recent years are finally increasing treatment options for patients
Innovative approaches in the management of gastrointestinal cancers
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
A growing community
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Epigenetic therapies – have they come of age?
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines
Can academic oncology compete with the career prospects offered by the pharma industry?
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
De-escalation of cancer treatments may be key to sustainability in oncology
Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients
Cancer treatment – how to wisely reduce its burden? A new ESMO tool to guide de-intensification
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach